RxDoctor Payments Data

Rama Mulpuri, MD

Internal Medicine · Saginaw, MINPI 1366439697

Payments from drug & device makers

$2,654in general payments, 2019–2025

Across 158 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$461
  • Novo Nordisk$460
  • AstraZeneca$243
  • Pfizer$177
  • Astellas Pharma US Inc$174
  • AbbVie$140
  • plus $998 from 20 others

What the payments were for

  • Food & beverage$2,52095%
  • Education$1044%
  • Other$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,654 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$166,849
Medicare patients
340
Services billed
2,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$345,347
OzempicSemaglutide153$226,108
JardianceEmpagliflozin179$191,209
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$72,752
RybelsusSemaglutide33$49,484
Tresiba Flextouch U-200Insulin Degludec41$42,398
TrulicityDulaglutide24$37,766
JanumetSitagliptin Phos/Metformin Hcl32$30,495
FarxigaDapagliflozin Propanediol30$29,913
XareltoRivaroxaban18$26,529
SynjardyEmpagliflozin/Metformin Hcl30$24,725
JanuviaSitagliptin Phosphate38$22,911
Lantus SolostarInsulin Glargine,hum.Rec.Anlog106$20,209
EntrestoSacubitril/Valsartan14$17,514
LinzessLinaclotide21$16,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$177$350,813323 claims
Novo NordiskOzempic, Rybelsus$460$275,591186 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$119$232,161230 claims
GSKTrelegy Ellipta, Breo Ellipta$111$85,62690 claims
MerckJanumet, Januvia$75$53,40670 claims
Lilly USA, LLCTrulicity$461$37,76624 claims
AstraZenecaFarxiga$243$29,91330 claims
Johnson & JohnsonXarelto$49$26,52918 claims
AbbVieLinzess, Synthroid$140$21,27666 claims
NovartisEntresto$70$17,51414 claims
Astellas Pharma US IncMyrbetriq$174$12,48812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →